These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21466414)

  • 21. [Development of glipizide push-pull osmotic pump controlled release tablets by using expert system and artificial neural network].
    Zhang ZH; Wang Y; Wu WF; Zhao X; Sun XC; Wang HQ
    Yao Xue Xue Bao; 2012 Dec; 47(12):1687-95. PubMed ID: 23460977
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Applicability of (SBE)7m-beta-CD in controlled-porosity osmotic pump tablets (OPTs).
    Okimoto K; Tokunaga Y; Ibuki R; Irie T; Uekama K; Rajewski RA; Stella VJ
    Int J Pharm; 2004 Nov; 286(1-2):81-8. PubMed ID: 15501004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preparation and in vitro/in vivo evaluation of sustained-release metformin hydrochloride pellets.
    Hu LD; Liu Y; Tang X; Zhang Q
    Eur J Pharm Biopharm; 2006 Oct; 64(2):185-92. PubMed ID: 16797948
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Push-pull osmotic pump for zero order delivery of lithium carbonate: development and in vitro characterization.
    Patel V; Chudasama A; Nivsarkar M; Vasu K; Shishoo C
    Pharm Dev Technol; 2012; 17(3):375-82. PubMed ID: 21284541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Simultaneous delivery of Nifedipine and Metoprolol tartarate using sandwiched osmotic pump tablet system.
    Kumaravelrajan R; Narayanan N; Suba V; Bhaskar K
    Int J Pharm; 2010 Oct; 399(1-2):60-70. PubMed ID: 20696225
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gastro-floating bilayer tablets for the sustained release of metformin and immediate release of pioglitazone: preparation and in vitro/in vivo evaluation.
    He W; Li Y; Zhang R; Wu Z; Yin L
    Int J Pharm; 2014 Dec; 476(1-2):223-31. PubMed ID: 25283698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A short-term cost-of-treatment model for type 2 diabetes: comparison of glipizide gastrointestinal therapeutic system, metformin, and acarbose.
    Ramsdell JW; Grossman JA; Stephens JM; Botteman MF; Arocho R
    Am J Manag Care; 1999 Aug; 5(8):1007-24. PubMed ID: 10558125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sustained-release versus immediate-release glipizide for treatment of type 2 diabetes mellitus in chinese patients: A randomized, double-blind, double-dummy, parallel-group, 12-week clinical study.
    Hsieh SH; Lin JD; Cheng HY; Ho C; Liou MJ
    Clin Ther; 2006 Sep; 28(9):1318-26. PubMed ID: 17062305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Investigation of an active film coating to prepare new fixed-dose combination tablets for treatment of diabetes.
    Kim JY; Kim DW; Kuk YM; Park CW; Rhee YS; Oh TO; Weon KY; Park ES
    Int J Pharm; 2012 May; 427(2):201-8. PubMed ID: 22330933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hot melt granulation: a facile approach for monolithic osmotic release tablets.
    Panda RR; Tiwary AK
    Drug Dev Ind Pharm; 2012 Apr; 38(4):447-61. PubMed ID: 21954892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and evaluation of osmotically controlled oral drug delivery system of glipizide.
    Verma RK; Garg S
    Eur J Pharm Biopharm; 2004 May; 57(3):513-25. PubMed ID: 15093601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Formulation design and characterization of an elementary osmotic pump tablet of flurbiprofen.
    Patel KN; Mehta TA
    PDA J Pharm Sci Technol; 2014; 68(4):333-46. PubMed ID: 25035256
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Controlled porosity solubility modulated osmotic pump tablets of gliclazide.
    Banerjee A; Verma PR; Gore S
    AAPS PharmSciTech; 2015 Jun; 16(3):554-68. PubMed ID: 25378281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a controlled release low dose class II drug-Glipizide.
    Jamzad S; Fassihi R
    Int J Pharm; 2006 Apr; 312(1-2):24-32. PubMed ID: 16481135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel solubility-modulated granules through porosity osmotic pump for controlled carvedilol delivery.
    Song QL; Li P; Li YM
    Pharm Dev Technol; 2012; 17(6):666-76. PubMed ID: 21486184
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and evaluation of osmotic pump tablets of naproxen sodium.
    Ramakrishna N; Mishra B
    Pharmazie; 2001 Dec; 56(12):958-62. PubMed ID: 11802660
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Designing of the fixed-dose gastroretentive bilayer tablet for sustained release of metformin and immediate release of atorvastatin.
    Oh JH; Eun Lee J; Jeong Kim Y; Oh TO; Han S; Jeon EK; Shin K; Kim DH; Hye Park C; Lee YJ
    Drug Dev Ind Pharm; 2016; 42(2):340-9. PubMed ID: 26467296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preparation and in vitro evaluation of sustained release tablet formulations of diclofenac sodium.
    Savaşer A; Ozkan Y; Işimer A
    Farmaco; 2005 Feb; 60(2):171-7. PubMed ID: 15752476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Controlling release of metformin HCl through incorporation into stomach specific floating alginate beads.
    Nayak A; Jain SK; Pandey RS
    Mol Pharm; 2011 Dec; 8(6):2273-81. PubMed ID: 22017707
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of pore-formers and plasticizers on the release kinetic of diltiazem hydrochloride from the controlled porosity osmotic pumps.
    Shokri J; H Zarrintan M; Ghanbarzadeh S; Arash Z; Farahani A; Adibkia K
    Drug Res (Stuttg); 2013 Aug; 63(8):414-9. PubMed ID: 23599037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.